Last reviewed · How we verify
NCT03837678
Epithelioid Sarcoma Natural History Study
trial in Epithelioid Sarcoma in 74 participants. Completed in 2 September 2021.
2 September 2021
Quick facts
| Lead sponsor | Epizyme, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 74 |
| Start date | 4 June 2018 |
| Primary completion | 2 September 2021 |
| Estimated completion | 2 September 2021 |
| Sites | 5 locations across United States |
Conditions studied
- Epithelioid Sarcoma — all drugs for Epithelioid Sarcoma →
Sponsor
Epizyme, Inc. — full company profile →
Who can join
10 and older, any sex, with Epithelioid Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multi-center, non-interventional retrospective medical records review. The study will involve identification of medical records of patients with confirmed locally advanced unresectable or metastatic ES, who initiated systemic therapy between January 1, 2000 and December 31, 2017. Data for the chart review will be extracted retrospectively from eligible subjects' charts (electronic or paper). Information on prior surgical treatment and neoadjuvant/adjuvant therapies for ES will also be collected for ineligible subjects with a locally advanced or metastatic ES diagnosis who did not initiated systemic therapy. Data collected will be anonymized by the investigators and will not be traceable back to individual subjects by the sponsor (i.e., no protected health information \[PHI\] will be collected).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03837678
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epithelioid Sarcoma
Currently open trials in the same condition.
- NCT05407441 — Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · Phase 1, PHASE2 · active not recruiting
- NCT05286801 — Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors · Phase 1, PHASE2 · active not recruiting
- NCT04390737 — Evaluate the Safety and Clinical Activity of HH2853 · Phase 1, PHASE2 · recruiting
- NCT03099681 — An Observational Study on Epithelioid Sarcoma · recruiting
- NCT02180867 — Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly D · Phase 2, PHASE3 · active not recruiting
Other Epizyme, Inc. trials
Trials by the same sponsor.
- NCT06068881 — A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lym · Phase 2 · withdrawn
- NCT05121103 — A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With R · Phase 1 · terminated
- NCT05205252 — A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. · Phase 1, PHASE2 · withdrawn
- NCT04762160 — SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicula · Phase 2 · terminated
- NCT04224493 — A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenal · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03837678 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Epizyme, Inc.
- Last refreshed: 7 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03837678.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing